ArticleTrauma case reports2025
Managing delayed union of fragility fractures of the pelvis successfully using romosozumab: A case report.
Article in Trauma case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fragility fractures of the pelvis (FFPs) are typically caused by minor trauma or without any trauma in older individuals with osteoporosis. In recent years, FFP incidence has increased considerably owing to the increasing number of individuals in the aging population as well as impaired daily life. Surgeries are the main treatment options for some types of FFPs; however, the potential of the use of romosozumab, an FDA-approved humanized monoclonal antibody that can bind and inhibit sclerostin, is yet to be evaluated. Romosozumab substantially increases bone mineral density (BMD) in the spine and the hip, improves bone strength, and prevents the occurrence of new fractures. Previous studies have demonstrated the efficacy of romosozumab in promoting fracture healing, including the healing of nonunion in some fractures. Herein, we present a case of a 61-year-old woman who had FFP delayed union, after falling 4 months before visiting our hospital. She presented with bilateral buttock and leg pain. Baseline BMD measured using dual-energy X-ray absorptiometry revealed a T-score of -3.8 and -3.2 for the lumbar spine and total hip, respectively. As the patient's BMD indicated a high risk of fractures, romosozumab was administered. Her pain improved 3 months after the medication. Computed tomography taken after 3 months revealed that the fracture had healed, suggesting that romosozumab is an effective medication for treating FFP delayed union and nonunion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.